医药魔方2023-07-26 10:06
7月24日,Syndax Pharmaceuticals和Incyte共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日,$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验,共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
药融云医药大数据2023-05-16 16:11
据CDE官网最新公示,成都苑东生物4类化药磷酸芦可替尼片的仿制药上市申请获受理。2022年,该JAK抑制剂全球大卖了$40亿,国内销售额也同比增长23%,达到4亿。目前,该品种在国内尚无仿制药获批,国内首仿药虚位以待。
截图来源:CDE官网
芦可替尼是由Incyte开发的选择性JAK抑制剂(JAK1/JAK...查看全文
智通财经APP获悉,当地时间6月13日,美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市,用于治疗严重斑秃成人患者。值得一提的是,这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉,美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA,治疗确诊新冠的住院患者时,baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特(INCY)$ 424B7 - Prospectus [Rule 424(b)(7)] Filed: 2017-03-10 AccNo: 0001104659-17-015827 Size: 347 KB 网页链接
$因塞特(INCY)$ 8-K/A [Amend] - Current report Filed: 2017-03-10 AccNo: 0001104659-17-015819 Size: 350 KBItem 9.01: Financial Statements and Exhibits 网页链接
$因塞特(INCY)$ CT ORDER - Confidential treatment order Filed: 2017-02-27 AccNo: 9999999997-17-001119 Size: 11 KB 网页链接
$因塞特(INCY)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2017-02-22 AccNo: 0001144204-17-010411 Size: 116 KB 网页链接
$因塞特(INCY)$ 8-K - Current report Filed: 2017-02-21 AccNo: 0001104659-17-010355 Size: 94 KBItem 1.01: Entry into a Material Definitive AgreementItem 3.02: Unregistered Sales of Equity SecuritiesItem 9.01: Financial Statements and Exhibits 网页链接
$因塞特(INCY)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2017-02-14 AccNo: 0001558370-17-000594 Size: 16 MB 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-02-13 AccNo: 0001422849-17-000063 Size: 8 KB 网页链接
$因塞特(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2017-02-14 AccNo: 0001104659-17-009316 Size: 59 KB 网页链接
$因塞特(INCY)$ 8-K - Current report Filed: 2017-02-14 AccNo: 0001104659-17-009294 Size: 61 KBItem 1.01: Entry into a Material Definitive AgreementItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$因塞特(INCY)$ 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] Filed: 2017-02-14 AccNo: 0001104659-17-009266 Size: 797 KB 网页链接